Business Development Manager Non-sterile Drug Product Development and Manufactur

Company Description

Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and our environment safer, healthier and more sustainable. From the food you eat, to the water you drink, to the medicines you rely on, Eurofins laboratories work with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic, and labelling is accurate.

Eurofins is dedicated to delivering testing services that contribute to the health and safety of society and the planet, and to its corporate responsibility to protect the environment and ensure diversity, equity, and inclusion across the entire network of Eurofins companies.

Job Description

Eurofins CDMO is a leading international Contract Development and Manufacturing Organization (CDMO) based in Europe. Our company focuses on drug product development and manufacturing for chemical/biological entities and drug substance development and manufacturing for biological entities. We support small and major biopharmaceutical companies in an innovative way to help them achieve their (pre)clinical milestones timely. Our facilities are perfectly designed for clinical and/or small-scale commercial batches for non-sterile or sterile dosage forms. With approximately 350 staff, we operate out of 8 sites in France, Belgium, and Italy.

To support our ambitious growth plan in formulation, analytical development, and manufacturing of clinical batches and small-scale commercial batches, we are today looking for a talented Business Development Manager for Non-Sterile Drug Product Development and Manufacturing.

Reporting to the Head of Business Development, you will work closely with our Technical Business Managers (compiling quotations) and our different Business Unit Managers (managing sites) to achieve your assigned objectives. The ideal candidate will be in charge of:

• Enlarging client portfolio through active prospection in Europe.
• Focusing on development projects particularly the earliest phases up to clinical development (Phase 1 to 2B) for chemical and/or biological compounds.
• Representing the CDMO division at relevant conferences, workshops, and tradeshows.
• Benchmarking our offering versus identified competitors or newcomers.

This position will primarily focus on our site in Ghent but can also serve our facilities located in Bordeaux (FR), Montpellier (FR), or Idron (FR) with whom the candidate will closely collaborate.

Qualifications

Graduating with a scientific degree (Engineer, MSc, PhD), we would expect at least 5 to 10 years of relevant experience in selling full package services from formulation development, and drug product development to packaging including analytical support and manufacturing for small or large molecules.
Good communicator, dynamic, strong business acumen with an understanding of the drug product development and manufacturing requirements for small molecules and biologics.
Even if autonomous, you like to feel part of a team.
You are willing to travel (30% of your time).
Excellent English, another language (French, Dutch/Flemish, or German) would be a plus.
This position would be ideally located in Ghent or surroundings. Nevertheless, we are open for good candidates in other locations with good flight connections.

Additional Information

We support your development! Do you feel you don’t match 100% of the requirements? Don’t hesitate to apply anyway! Eurofins companies are committed to supporting your career development.

We embrace diversity! Eurofins network of companies believe in strength and innovation through diversity, being an Equal Opportunity Employer. We prohibit discrimination against employees or applications based on gender identity and/or expression, race, nationality, age, religion, sexual orientation, disability, and everything else that makes employees of Eurofins companies unique.

Sustainability matters to us!We are well on our way to achieving our objective of carbon neutrality by 2025, through a combination of emission reduction and compensation initiatives. We encourage our laboratory leaders to make sustainable changes at their local level, and in addition to their initiatives we also count on our dedicated carbon reduction team to help us to achieve this goal!

Find out more in our career page: https://careers.eurofins.com/

Company description: Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and our environment safer, healthier and more sustainable. From the food you eat, to the water you drink, to the medicines you rely on, Eurofins laboratories work with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate.

The Eurofins network of companies is the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

In over 35 years, Eurofins has grown from one laboratory in Nantes, France to 62,000 staff across a decentralised and entrepreneurial network of over 900 laboratories in 62 countries. Eurofins companies offer a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products.

In 2022, Eurofins generated total revenues of EUR 6.7 billion, and has been among the best performing stocks in Europe over the past 20 years.